Jill Roberts Center for Inflammatory Bowel Disease

Publications

Found 8 results
Author Title [ Type(Desc)] Year
Filters: First Letter Of Last Name is U  [Clear All Filters]
Journal Article
Marion JF, Waye JD, Present DH, Israel Y, Bodian C, Harpaz N, Chapman M, Itzkowitz S, Steinlauf AF, Abreu MT et al..  2008.  Chromoendoscopy-targeted biopsies are superior to standard colonoscopic surveillance for detecting dysplasia in inflammatory bowel disease patients: a prospective endoscopic trial.. Am J Gastroenterol. 103(9):2342-9.
Dulai PS, Singh S, Casteele NVande, Meserve J, Winters A, Chablaney S, Aniwan S, Shashi P, Kochhar G, Weiss A et al..  2020.  Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis.. Clin Gastroenterol Hepatol. 18(13):2952-2961.e8.
Agrawal M, Cohen-Mekelburg S, Kayal M, Axelrad J, Galati J, Tricomi B, Kamal K, Faye AS, Abrudescu P, Scherl E et al..  2019.  Disability in inflammatory bowel disease patients is associated with race, ethnicity and socio-economic factors.. Aliment Pharmacol Ther. 49(5):564-571.
Scher JU, Sczesnak A, Longman RS, Segata N, Ubeda C, Bielski C, Rostron T, Cerundolo V, Pamer EG, Abramson SB et al..  2013.  Expansion of intestinal Prevotella copri correlates with enhanced susceptibility to arthritis.. Elife (Cambridge). 2:e01202.
Cohen-Mekelburg S, Rosenblatt R, Gold S, Shen N, Fortune B, Waljee AK, Saini S, Scherl E, Burakoff R, Unruh M.  2019.  Fragmented Care is Prevalent Among Inflammatory Bowel Disease Readmissions and is Associated With Worse Outcomes.. Am J Gastroenterol. 114(2):276-290.
Kayal M, Ungaro RC, Riggs A, Kamal K, Agrawal M, Cohen-Mekelburg S, Axelrad J, Faye A, Scherl E, Lawlor G et al..  2021.  Ileal Pouch Anal Anastomosis for the Management of Ulcerative Colitis Is Associated With Significant Disability.. Clin Gastroenterol Hepatol.
Sandborn WJ, Feagan BG, Fedorak RN, Scherl E, Fleisher MR, Katz S, Johanns J, Blank M, Rutgeerts P.  2008.  A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease.. Gastroenterology. 135(4):1130-41.
Faleck DM, Winters A, Chablaney S, Shashi P, Meserve J, Weiss A, Aniwan S, Koliani-Pace JL, Kochhar G, Boland BS et al..  2019.  Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease But Not Ulcerative Colitis.. Clin Gastroenterol Hepatol. 17(12):2497-2505.e1.